Vi­iV, GSK gam­ble a sur­prise $130M chip in a high-stakes HIV play­off with Gilead

Glax­o­SmithK­line $GSK hasn’t had much to boast about over the last cou­ple of years when it comes to new drug de­vel­op­ment. But Vi­iV — the HIV spe­cial­ist which it con­trols a ma­jor­i­ty stake in — has proven to be a no­table ex­cep­tion to that rule.

To­day, Vi­iV con­tin­ued to live up to its star billing in­side GSK cir­cles, not­ing that it filed twin ap­pli­ca­tions at the FDA and the EMA for a com­bi­na­tion of do­lute­gravir (Tivicay) and rilpivirine (J&J’s Edu­rant), which it plans to mar­ket as the world’s first two-drug main­te­nance ther­a­py for keep­ing a lid on the lethal virus.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER